These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6700270)

  • 21. Multiple risk factor intervention trial produces an unexpected result.
    Rautaharju PM
    Can Med Assoc J; 1983 Jan; 128(2):113-4. PubMed ID: 6848151
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential to reduce death by cardiological treatment.
    Rosolova H; Simon J
    Eur Heart J; 1999 Oct; 20(19):1376-7. PubMed ID: 10487797
    [No Abstract]   [Full Text] [Related]  

  • 23. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).
    Dzau VJ; Antman EM; Black HR; Hayes DL; Manson JE; Plutzky J; Popma JJ; Stevenson W
    Circulation; 2006 Dec; 114(25):2850-70. PubMed ID: 17179034
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment and care of coronary artery syndrome in Finland].
    Vikman S; Airaksinen J; Tierala I; Peuhkurinen K; Majamaa-Voltti K; Niemelä M; Tuunanen H; Niemelä K; Nieminen MS
    Duodecim; 2005; 121(7):753-9. PubMed ID: 15909962
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
    Vaccaro O; Eberly LE; Neaton JD; Yang L; Riccardi G; Stamler J;
    Arch Intern Med; 2004 Jul; 164(13):1438-43. PubMed ID: 15249353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease.
    Veit CT
    Med Decis Making; 2004; 24(4):330-50. PubMed ID: 15271272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The correspondence between coronary heart disease mortality and risk factor prevalence among states in the United States, 1991-1992.
    Byers T; Anda R; McQueen D; Williamson D; Mokdad A; Casper M; Ford E; Marks J
    Prev Med; 1998; 27(3):311-6. PubMed ID: 9612821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
    Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
    Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical end points in coronary stent trials: a case for standardized definitions.
    Cutlip DE; Windecker S; Mehran R; Boam A; Cohen DJ; van Es GA; Steg PG; Morel MA; Mauri L; Vranckx P; McFadden E; Lansky A; Hamon M; Krucoff MW; Serruys PW;
    Circulation; 2007 May; 115(17):2344-51. PubMed ID: 17470709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High blood pressure and end-organ damage.
    Cutler JA
    J Hypertens Suppl; 1996 Dec; 14(6):S3-6. PubMed ID: 9023707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRFIT and the Oslo study.
    JAMA; 1983 Feb; 249(7):893-4. PubMed ID: 6337274
    [No Abstract]   [Full Text] [Related]  

  • 34. Forms control and error detection procedures used at the Coordinating Center of the Multiple Risk Factor Intervention Trial (MRFIT).
    DuChene AG; Hultgren DH; Neaton JD; Grambsch PV; Broste SK; Aus BM; Rasmussen WL
    Control Clin Trials; 1986 Sep; 7(3 Suppl):34S-45S. PubMed ID: 3802845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary artery disease in the elderly.
    Satler LF; Green CE; Wallace RB; Rackley CE
    Am J Cardiol; 1989 Jan; 63(3):245-8. PubMed ID: 2642635
    [No Abstract]   [Full Text] [Related]  

  • 36. Statistical design considerations in the NHLI multiple risk factor intervention trial (MRFIT). The Multiple Risk Factor Intervention Trial Group.
    J Chronic Dis; 1977 May; 30(5):261-75. PubMed ID: 863996
    [No Abstract]   [Full Text] [Related]  

  • 37. Mortality and the multiple risk factor intervention trial.
    Stallones RA
    Am J Epidemiol; 1983 Jun; 117(6):647-50. PubMed ID: 6344618
    [No Abstract]   [Full Text] [Related]  

  • 38. Interpreting data from the MRFIT.
    Berglund G
    Circulation; 1991 Dec; 84(6):2608-9. PubMed ID: 1959215
    [No Abstract]   [Full Text] [Related]  

  • 39. Downstream Change of the Primary Endpoint in the ISCHEMIA Trial: the Elephant in the Room.
    Correia LCL; Rassi Junior A
    Arq Bras Cardiol; 2018 Aug; 111(2):213-214. PubMed ID: 30183989
    [No Abstract]   [Full Text] [Related]  

  • 40. Coronary Heart Disease Prevention: The Multiple Risk Factor Intervention Trial (MRFIT).
    Borhani NO
    West J Med; 1974 Nov; 121(5):418. PubMed ID: 18747472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.